About the HCMA

HCM is known by many names and it is important to understand that it is, for the most part, one disease. Oftentimes, those with hypertrophic obstructive cardiomyopathy(HOCM, oHCM), apical hypertrophic cardiomyopathy, or asymmetric septal hypertrophic cardiomyopathy think this is a completely different disease. When in reality it is all hypertrophic cardiomyopathy with varied physical presentations. Put differently, the words "obstructive," "apical," or "asymmetric septal" are just descriptions of the current state of the disease.

This website will expand your knowledge of hypertrophic cardiomyopathy as well as issues important to our community by providing clinically reviewed information, support options and member services.

The HCMA is the preeminent organization improving the lives of those with hypertrophic cardiomyopathy, HCM, preventing untimely deaths and advancing global understanding. Founded in 1996 we are committed to providing support, education, advocacy and advancing research, understanding and care to those with HCM.

Should you have questions at any point while reviewing this website, please reach out the the HCMA office at: 973-983-7429 or email us at support@4hcm.org and we will respond as soon as possible.

Hypertrophic cardiomyopathy (HCM) is a common genetic disorder that affects people regardless of gender, ethnicity, age or geographic location.

Learn more about future therapy options, including investigational medications, genetic therapy trials.

Investigational Therapies

From Tenaya Therapeutics:

The first person has received a dose of TN-201 gene therapy for HCM. TN-201 is being developed to treat HCM caused by MYBPC3 genetic mutations. Variations in the MYBPC3 gene are the most common genetic cause of HCM. TN-201 gene therapy delivers a working MYBPC3 gene into heart cells to address the underlying cause of disease.

This first-in-human clinical trial is intended to help us understand the safety of TN-201 therapy, any potential side effects associated with

treatment, the best dose of TN-201 and the changes that occur over time to HCM symptoms and heart function following treatment.

The first patient was dosed at the Cleveland Clinic HCM Center in Ohio.

MyPeak-1 is actively enrolling patients with nonobstructive HCM who have the MYBPC3 genetic mutation. In addition to the Cleveland Clinic, the study is being conducted at leading HCM centers across the U.S.

Tenaya Therapeutics is committed to discovering and developing new treatments for heart conditions.

Tenaya expects to report initial data from the MyPeak-1 study in 2024.

*************

The HCMA offer our congratulations to the Tenaya team on this incredible milestone.

Search our video archive for more content from Lisa and her guests on Tales from the Heart, Featured Centers of Excellence from the Big Hearted Warriors Tour, HCM Awareness Day archives, information on Camzyos and other therapies, and upcoming or active trials.